BioSpace News Archive

Albany NY, United States: Tooth positioners are recommended to patients to achieve flawless alignment of the teeth as part of the final procedure in orthodontic treatment.

Spexis AG a clinical-stage biopharmaceutical company, focused on rare diseases and oncology with an initial focus on chronic respiratory diseases published the invitation to its Annual General Meeting on April 26, 2022.

Sanofi announced that the French Autorité des marchés financiers has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.

Takeda announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting of Shareholders on June 29, 2022.

Royal Philips, a global leader in health technology, is showcasing its integrated portfolio of diagnosis, guidance, and treatment solutions for atrial fibrillation at the 2022 European Heart Rhythm Association Annual Meeting.

Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced the successful completion of the first-in-human dose escalating study of ZZ6398 in healthy volunteers.

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved or mildly reduced ejection fraction.

Sage Therapeutics, Inc. announced the presentation of data from the Phase 2 LUMINARY Study that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease.

Eli Lilly and Company announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® in patients with RET fusion-positive non-small cell lung cancer.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO™, an investigational oral antiviral COVID-19 medicine, will be presented at the 2022 European Congress of Clinical Microbiology & Infectious Diseases.